Amar Maletira
Analyst · Stifel. Your line is now open
Thank you, Bill. Fiscal Q4 revenue of $224.1 million exceeded our guidance midpoint of $220 million. OSP revenue exceeded the guidance range while NSE was above the guidance midpoint. Revenue was up 2% year-over-year, driven by strong performance in our OSP segment that offset the decline in NSE. Our operating income at $30.2 million grew $13.3 million or 78.7% year-over-year. Operating margin of 13.5% was towards the high end of the guidance range and was up 580 basis points year-over-year, as a result of strong OSP performance and good operating expense management in NSE. Overall, Viavi operating expenses declined 7.6% year-over-year or $9.2 million, driven by G&A expense reduction and R&D spend optimization. EPS at $0.10 was at the high end of the guidance range which is 150% increase from $0.04 a year ago. Now, moving to the results by business segment, starting with NSE. NSE revenue at $161.1 million declined 4.8% year-over-year, driven by a 9.4% decline in the SE segment and a 3.6% decline in the NE segment. The year-on-year SE revenue decline impacted both the enterprise and assurance businesses with mature products declining at a steeper pace compared to the growth in new products. NSE gross margins at 64.8% increased 10 basis points year-over-year due to product mix. NSE’s operating margin at 1.5%, increased 300 basis points year-over-year, as a result of operating expense reduction. The book-to-bill ratio for NE, which is our core instrument business, was above 1 while SE had a book-to-bill of below 1, primarily due to mature product runoff. As a result, overall, NSE book-to-bill ratio was below 1. Now turning to OSP. OSP revenue at $63 million grew 24.8% from a year ago levels, driven by higher demand in the anti-counterfeiting business. Gross margins at 59.4% increased 360 basis points, and operating margin at 44.1% improved 570 basis points from last year due to higher revenue, favorable product mix, and higher factory utilization. Moving to fiscal year 2016. For the fiscal year 2016 Viavi’s revenue at $906.3 million grew 3.7% from fiscal 2015, driven by growth in our anti-counterfeiting business within the OSP segment. NSE revenue declined 3.4% due to steep declines in our mature assurance business. Our core instruments business has stabilized and was roughly flat year-over-year. Operating margin for Viavi at 12.8% was a 500 basis-point improvement versus a year ago. Net income for the year at $90 million more than doubled from $44 million a year ago. This resulted in EPS for the year doubling to $0.38 from $0.19 versus prior year. This profit performance was a result of revenue growth in our OSP segment and operating expense reduction in our NSE segment, primarily in G&A and R&D spend optimization. Driving operational efficiency will continue to be an important area of focus in fiscal 2017 and beyond. Today, we also announced that we’ll be restating our Q1, Q2 and Q3 financial statements to correct an error in our calculation of GAAP only non-cash income tax expense in a foreign jurisdiction. This was corrected during Q4 and so does not impact full year fiscal 2016 GAAP results being reported today. While the error was not material on a standalone basis for any individual quarter, based on the cumulative effect for the first half of the fiscal year, we determined that the restatement was warranted. This GAAP tax expense restatement does not impact our previously reported non-GAAP results. On a GAAP basis, fiscal year 2016 showed a loss from continuing operations before tax of $45.9 million, an improvement from fiscal 2015 loss of $105.3 million. Fiscal 2016 GAAP losses from continuing operations before taxes reflects the impairment of goodwill related to the SE segment, partially offset by investment gains from the sale of Lumentum stock. Fiscal year 2016 GAAP EPS loss from continuing operations of $0.22 was lower than the prior fiscal year with a GAAP EPS loss from continuing operations of $0.57. Now, turning to the balance sheet, our total cash and short-term investments ending balance was approximately $980 million, which includes the remaining 7.2 million shares in Lumentum valued at $171.3 million. During the quarter, we sold approximately 2 million shares of Lumentum stock with an average selling price of $24.86 per share, resulting in net proceeds of $48.5 million. Our book cost basis on these shares is approximately $8.58 per share. As a result, we realize on GAAP only P&L an accounting gain of approximately $31.8 million. Following the end of fiscal year 2016, we sold an additional 2.2 million shares, bringing the number of Lumentum shares we sold to-date to 6.7 million out of the original 11.7 million shares received in August 2015. Cumulatively, these shares were sold at an average selling price of $24.95 per share, resulting in net proceeds of $166 million. During fiscal year 2016, we repurchased a total of 7.3 million Viavi common shares at $44.5 million with an average cost basis of $6.11. This included the repurchase of approximately 1 million shares of Viavi stock under the new share buyback program announced in February 2016. We will continue to be opportunistic to monetize our Lumentum share position and actively pursue the repurchase of our own stock. Our GAAP operating cash flow from operations for the quarter was $17.9 million. At the end of fiscal year 2016, we took a goodwill impairment charge on the SE segment of $91.4 million before tax. This was a result of annual impairment testing of our goodwill and an ongoing assessment of our SE business. At the end of fiscal year 2016, goodwill of $152.1 million is comprised of NE at $143.8 million, OSP at $8.3 million and SE at zero. Now, turning to our guidance. We expect fiscal first quarter of 2017 revenue to be in the range of $201 million to $217 million, operating margin at 11.4% plus or minus 1%, and EPS to be $0.06 to $0.08. We expect NSE revenue to be at $153 million plus or minus $6 million with operating margin at 1% plus or minus 1%. We expect OSP revenue to be at $56 million plus or minus $2 million, with operating margin at 40% plus or minus 1%. Our tax expense is expected to be about $4.5 million. We expect other income and expenses to be a net expense of $2.5 million and our share count to be approximately 238 million shares. Now, I will now turn the call over to Oleg.